4//SEC Filing
Onyia Jude 4
Accession 0000914475-25-000067
CIK 0000914475other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 6:35 PM ET
Size
19.7 KB
Accession
0000914475-25-000067
Insider Transaction Report
Form 4
Onyia Jude
Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-02-13$116.83/sh−1,432$167,306→ 16,846 total - Sale
Common Stock
2025-02-13$116.75/sh−1,447$168,933→ 18,089 total - Exercise/Conversion
Common Stock
2025-02-13+2,690→ 19,536 total - Exercise/Conversion
Common Stock
2025-02-13+2,717→ 18,278 total - Award
Stock Option
2025-02-12+54,645→ 54,645 totalExercise: $117.18Exp: 2035-02-12→ Common Stock (54,645 underlying) - Award
Restricted Stock Unit
2025-02-12+10,241→ 10,241 total→ Common Stock (10,241 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-13−2,717→ 5,434 total→ Common Stock (2,717 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-13−2,690→ 8,070 total→ Common Stock (2,690 underlying)
Footnotes (9)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F4]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- [F6]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F7]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.
- [F8]This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, and will vest as to 2,717 shares on February 13, 2026, and 2,717 shares on February 13, 2027, subject to the terms and conditions of the award.
- [F9]This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, and will vest as to 2,690 shares on February 13, 2026, 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001894425
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 6:35 PM ET
- Size
- 19.7 KB